compani
thought call
lilli call reveal major surpris new guidanc
pend dermira acquisit read favor total revenu non-
gaap ep re-affirmed month ago weaker thought
trend trulic taltz jardianc look quit good
volum growth suffici off-set price headwind
oper project continu margin improv trend
go requir step-up bd unlik mani biopharma
peer overal despit strong ytd perform drg index wed still
buyer share given differenti growth young product cycl lack
major near-term pipelin mani event low expect
mirikizumab olumi ad verzenio adjuv breast
reiter buy rate rais po due estim chang
trulic jardianc sale grew overal market
trulic market leader despit rybelsu launch novo nordisk
upsid high-dos cv benefit label addit updat
dian-tu solanezumab provid howev lilli caution interpret
studi given small sampl size dont get impress lot embed
valu alzheim olumi file ad eu jpn
lilli hope push dose us remain realist given known
safeti issu jaki class lilli also see lebrikizumab potenti best-in-class
therapi ad vs dupix monthli mainten dose differenti
pegilodecakin major driver armo acquisit read neg two
phase studi longer pursu alreadi remov model
updat model forecast revenu prior
increas sg expens given updat opex guidanc
rais non-gaap ep estim
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani
larg diversifi
biopharmaceut compani develop drug
treatment varieti disord includ
diabet migrain cancer rang
busi develop drug
year time
compani retain focu almost exclus
remain differenti versu peer
revenu non-gaap ep remain
bullish lilli key valu driver trulic
jardianc taltz psoriasi olumi
arthriti emgal migrain verzenio
overal view risk reward profil lilli
compel high qualiti differenti growth
modest expect ad pipelin valu
compani januari
million
compani januari
compani
price object base probability-adjust net present valu npv
analysi franchis vertic includ endocrinolog oncolog
pharmaceut product earli pipelin asset well
approxim net cash use wacc rang approv
product pipelin product depend stage develop appli
termin valu rang cardiolog pipelin base project sale
declin follow loss exclus within busi vertic
risk price object better expect launch compet
product emerg clinic data pipelin asset confirm prior
observ failur effect commerci approv product potenti
drug price system restructur us
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
compani januari
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani januari
